Breaking News Instant updates and real-time market news.

AAPL

Apple

$179.55

-1.44 (-0.80%)

, TWTR

Twitter

$31.30

-1.42 (-4.34%)

08:55
11/30/18
11/30
08:55
11/30/18
08:55

Notable open interest changes for November 30th

Thursday's total option volume of 18.4 million contracts resulted in net open interest growth of 2.79 million calls and 2.87 million puts. Apple (AAPL), Twitter (TWTR), Facebook (FB) and Bank of America (BAC) saw the greatest growth. Top five new positions opened include 86k Twitter (TWTR) Jan-20 70 calls, 25k J C Penney (JCP) Jan-20 1 puts, 24k Apple (AAPL) Dec-18 180 puts, 24k Apple (AAPL) Dec-18 180 calls and 21k Arconic (ARNC) Dec-18 22 calls.

AAPL

Apple

$179.55

-1.44 (-0.80%)

TWTR

Twitter

$31.30

-1.42 (-4.34%)

FB

Facebook

$138.61

1.88 (1.38%)

BAC

Bank of America

$28.04

-0.4 (-1.41%)

  • 04

    Dec

  • 12

    Feb

AAPL Apple
$179.55

-1.44 (-0.80%)

11/28/18
WEDB
11/28/18
NO CHANGE
Target $275
WEDB
Outperform
Apple price target lowered to $275 from $310 at Wedbush
Wedbush analyst Daniel Ives lowered his price target for Apple to $275 from $310 to reflect his reduced estimates and softer near-term iPhone data points. While the recent selloff in the shares has been a "painful one that is hard to stomach" for tech investors, he strongly believes that the valuation on the name at current levels and further monetization of its 750M-plus active iPhone installed base through future upgrades and a $50B-plus services revenue stream speaks to his bullish thesis on Apple for the coming years which remains unchanged. Nonetheless, Ives ultimately believes Apple will need to seriously contemplate pricing changes and/or design changes with the next cycle of iPhones slated for the fall of 2019 to drive a surge of upgrade activity that has moved out of FY19 and into FY20 as well as significantly invest in its content/services strategy over the next 12-18 months to drive more growth initiatives. He reiterates an Outperform rating on the shares.
11/29/18
SBSH
11/29/18
NO CHANGE
SBSH
Citi consumer electronics survey positive for Corning, negative for GoPro
Citi surveyed 60 retail and electronics stores in the U.S. during mid-November to inquire about promotions, sell-through, and preferences for various consumer electronics products, analyst Jim Suva tells investors in a research note. The analyst calls television the "clear winner," followed by video game accessories and wireless speakers. The results point to continued size migration to 50 inch-plus TVs and strong elasticity of demand for price promotions, says Suva. He believes this benefits Corning (GLW). The analyst also finds the video gaming accessories trends as positive for Logitech (LOGI). Fitness trackers and smartwatch trends are neutral for Fitbit (FIT) and positive for Apple (AAPL), while digital camera trends negative for GoPro (GPRO), adds Suva.
11/30/18
JPMS
11/30/18
NO CHANGE
Target $266
JPMS
Overweight
Apple recent selloff presents opportunity for investors, says JPMorgan
The 19% decline in Apple shares since the company's fiscal Q4 earnings report appears to have already priced in an "overly bearish scenario" of a greater than 10% iPhone volume decline in fiscal 2019, the impact of multi-year volume declines on Services, and potential new tariffs, JPMorgan analyst Samik Chatterjee tells investors in a research note. However, based on the analyst's checks, he does not find a need to tweak his iPhone volume forecasts for fiscal 2019 and 2020 further at this time. He believes the current valuation "sets a fairly low bar" on Apple shares. Chatterjee keeps an Overweight rating on Apple with a $266 price target.
11/30/18
MSCO
11/30/18
NO CHANGE
Target $253
MSCO
Overweight
Apple 'worst case' for tariffs could lower FY19 EPS 10%-20%, says Morgan Stanley
After President Donald Trump alluded to the potential for tariffs being placed on Apple iPhones and laptops imported from China in a recent interview with the Wall Street Journal, Morgan Stanley analyst Katy Huberty said that Apple relocating its final assembly base out of China, and even Asia more broadly, is "largely inconceivable" given that China is one of the only countries that can provide such a large and low-cost labor force with the expertise in manufacturing and tooling that is required to assemble over 300M devices annually. She believes the most realistic scenario is to keep the supply chain largely intact in the near-term and either pass the tariff cost to the consumer or absorb the cost of the tariff internally. If Apple were to pass the cost off to consumers, Huberty believes it could face significant demand and unit headwinds. However, if Apple were to fully absorb the full 10-25% tariff, the cost of the tariffs could ultimately impact FY19 EPS by $1 in the case of a 10% tariff and about $2.50 in the case of a 25% tariff, Huberty tells investors. Consensus for Apple's FY19 EPS is currently $13.45. Huberty has an Overweight rating and $253 price target on Apple shares.
TWTR Twitter
$31.30

-1.42 (-4.34%)

10/26/18
UBSW
10/26/18
NO CHANGE
Target $44
UBSW
Buy
Twitter successfully climbing 'wall of worry,' says UBS
UBS analyst Eric Sheridan said Twitter's Q3 report showed very strong ad revenue trends with material quarter-over-quarter ad business growth, stable trends off a strong base in Japan, and continued progress in video. The analyst said the company climbed almost every "wall of worry" of investors concerns and he believes they can outperform over the next 12 months. Sheridan reiterated his Buy rating and $44 price target on Twitter shares.
10/26/18
OPCO
10/26/18
UPGRADE
Target $37
OPCO
Outperform
Twitter upgraded to Outperform from Perform at Oppenheimer
Oppenheimer analyst Jason Helfstein upgraded Twitter to Outperform from Perform, telling investors in a research note that he believes within the scope of Social Media, Twitter shares offer reasonable value with reduced execution risk. Helfstein is optimistic that ad pricing has stabilized and expenses should grow slower than revenue in 2019. He has a $37 price target on the shares.
10/26/18
10/26/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Tractor Supply (TSCO) upgraded to Outperform from Sector Perform at RBC Capital, to Outperform from Neutral at Wedbush, and to Neutral from Underperform at BofA/Merrill. 2. Twitter (TWTR) upgraded to Outperform from Perform at Oppenheimer with analyst Jason Helfstein saying he believes within the scope of Social Media, Twitter shares offer reasonable value with reduced execution risk. 3. First Solar (FSLR) upgraded to Market Perform from Underperform at JMP Securities with analyst Joseph Osha citing valuation following the stock's 35% decline since the end of May. 4. GrubHub (GRUB) upgraded to Conviction Buy from Buy at Goldman Sachs, to Buy from Neutral at DA Davidson, and to Buy from Hold at Stifel. 5. Six Flags (SIX) upgraded to Neutral from Underperform at Macquarie with analyst Matthew Brooks saying he believes negative catalysts have passed and valuation is more balanced. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/26/18
MKMP
11/26/18
NO CHANGE
Target $190
MKMP
Buy
MKM Partners lowers price targets on Alphabet and Facebook
MKM Partners analyst Rob Sanderson lowers his price target on Alphabet (GOOGL) to $1,365 from $1,465 and on Facebook (FB) to $190 from $230 as part of his broader research note for the Internet Applications and Media sector. The analyst states that both of these stocks have been underperforming the Nasdaq on 1-month, 3-month, and year-to-date basis, but believes that Alphabet's underperformance has more to do with a rotation away from growth given its "remarkably consistent" performance and its expected moderating traffic acquisition rate costs. Sanderson says that while Facebook stock is the "furthest from its intrinsic value", it continues to face a "challenging event path with engagement shift toward lower monetizing apps" and the expected cost increase to build greater "safety and security competencies". He also believes that Facebook business model will normalize at "much lower profit margin" because of these added costs. The analyst keeps Alphabet and Facebook ratings at Buy. As part of his research note, Sanderson also maintains a Buy rating on Twitter (TWTR) with a price target of $43. The analyst contends that the company has "compelling upside potential as monetization catches up to engagement growth", with added optionality coming from potential "service breaks-through to the mass market."
FB Facebook
$138.61

1.88 (1.38%)

11/13/18
OPCO
11/13/18
NO CHANGE
Target $16
OPCO
Outperform
EverQuote price target lowered to $16 from $23 at Oppenheimer
Oppenheimer analyst Jason Helfstein lowered his price target for EverQuote (EVER) to $16 from $23 after management lowered 2018 VMM guidance 5% on less effective traffic conversion from creative advertisement fatigue, adjusting to new Facebook (FB) ad policies, and pushing higher volumes to providers in lower seasonal period. The analyst reiterates an Outperform rating on EverQuote on favorable risk/reward for long-term opportunity to penetrate $9B insurance advertising market.
11/16/18
STFL
11/16/18
NO CHANGE
STFL
Buy
Facebook path to rebuild credibility 'long and difficult,' says Stifel
Stifel analyst Scott Devitt said the probability of change at the top of Facebook is low, given that Mark Zuckerberg controls the majority of Facebook voting power, but Devitt believes the "campaign trail to rebuild credibility will be long and difficult" following the recent critical articles in The New York Times and Wall Street Journal. Facebook's board and management could accelerate the credibility rebuild by considering making a or changes at the top, which Devitt thinks would be viewed positively "by the vast majority of constituents." The analyst maintains a Buy rating on Facebook shares.
11/13/18
ADAM
11/13/18
NO CHANGE
Target $18
ADAM
Buy
EverQuote price target lowered to $18 from $23 at Canaccord
Canaccord analyst Michael Graham lowered his price target on EverQuote (EVER) to $18 from $23 following in line Q3 results. The company said quote requests declined from the revamp of its ad units in the face of policy changes at Facebook (FB) along with the crowding out from political ads. Management said they see the same circumstances affecting business so far in Q4. Graham maintained his Buy rating on EverQuote shares.
BAC Bank of America
$28.04

-0.4 (-1.41%)

11/15/18
11/15/18
NO CHANGE

Morgan Stanley says 13F a 'clear signal' of value Buffett sees in financials
Following the release last night of 13F filings detailing the holdings of large investors, including Berkshire Hathaway (BRK.A), Morgan Stanley analyst Kai Pan noted that the filing from Warren Buffett's Berkshire revealed increased stakes in Bank of America (BAC), U.S. Bancorp (USB) and Goldman Sachs (GS) along with new stakes in JPMorgan (JPM), PNC Financial (PNC) and Travelers (TRV). The analyst sees these investments, along with the fact that Berkshire's s financial holdings stood at 46% of its overall $203B equity portfolio as of quarter end, as a "clear signal" of the value that Buffett sees in financials, Pan tells investors. He adds that he views Buffett's new stake in Oracle (ORCL) as another "notable" new purchase.
09/25/18
WOLF
09/25/18
INITIATION
Target $40
WOLF
Outperform
Bank of America initiated with an Outperform at Wolfe Research
Wolfe Research analyst Steven Chubak initiated Bank of America with an Outperform and $40 price target.
09/19/18
OPCO
09/19/18
NO CHANGE
OPCO
Outperform
U.S. banks 'in very good shape,' says Oppenheimer, favorites include BofA, Citi
Oppenheimer analyst Chris Kotowski tells investors in a research note that the U.S. banking group is on solid footing with balance sheets less risky than at any time over the last 33 years the firm covered the group and says his favorite bank stocks are Outperform-rated Bank of America (BAC), Citi (C), CIT (CIT) and Goldman Sachs (GS). However, Kotowski notes that banks are trading at an average relative P/E of just ~66% relative to the S&P 500 and returning to a historical avg valuation of 73%-80% range would imply over a thousand basis points of outperformance by the group. In his view, the U.S. banks are, on the whole, in "very good" shape.
07/17/18
BARD
07/17/18
NO CHANGE
Target $30
BARD
Neutral
Baird would be buyers of Bank of America on weakness
Baird analyst David George said he would remain a buyer of Bank of America shares on any weakness, stating that its operating leverage was impressive in Q2 and should continue along with solid execution. George maintained his Neutral rating and $30 price target on Bank of America shares.

TODAY'S FREE FLY STORIES

HPQ

HP Inc.

$20.17

0.05 (0.25%)

, XRX

Xerox

$38.95

0.295 (0.76%)

20:56
11/17/19
11/17
20:56
11/17/19
20:56
Hot Stocks
Fly Intel: Top five weekend stock stories »

Catch up on the…

HPQ

HP Inc.

$20.17

0.05 (0.25%)

XRX

Xerox

$38.95

0.295 (0.76%)

GOLD

Barrick Gold

$16.57

-0.095 (-0.57%)

PCG

PG&E

$7.41

0.71 (10.60%)

FOX

Fox Corp.

$33.60

0.14 (0.42%)

FOXA

Fox Corp.

$34.26

0.04 (0.12%)

SNE

Sony

$62.03

0.23 (0.37%)

BR

Broadridge

$119.80

0.485 (0.41%)

MDT

Medtronic

$112.11

2.9 (2.66%)

DIS

Disney

$144.63

-2.56 (-1.74%)

BRK.A

Berkshire Hathaway

$329,361.11

266.11 (0.08%)

BRK.B

Berkshire Hathaway

$219.74

0.38 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 26

    Nov

  • 09

    Dec

  • 07

    Jan

RCEL

Avita Medical

$8.13

-0.06 (-0.73%)

20:39
11/17/19
11/17
20:39
11/17/19
20:39
Hot Stocks
Avita Medical appoints David McIntyre CFO »

AVITA Medical announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EIDX

Eidos Therapeutics

$46.58

1.33 (2.94%)

20:37
11/17/19
11/17
20:37
11/17/19
20:37
Recommendations
Eidos Therapeutics analyst commentary  »

Piper Jaffray sees Eidos…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 21

    Nov

COO

Cooper Companies

$301.97

2.64 (0.88%)

20:30
11/17/19
11/17
20:30
11/17/19
20:30
Recommendations
Cooper Companies analyst commentary  »

Piper Jaffray reiterates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

CRM

Salesforce

$163.20

0.18 (0.11%)

20:21
11/17/19
11/17
20:21
11/17/19
20:21
Recommendations
Salesforce analyst commentary at Jefferies »

Salesforce price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 03

    Dec

  • 16

    Dec

CCMP

Cabot Microelectronics

$155.89

2.68 (1.75%)

20:15
11/17/19
11/17
20:15
11/17/19
20:15
Earnings
Breaking Earnings news story on Cabot Microelectronics »

Cabot Microelectronics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

CCMP

Cabot Microelectronics

$155.89

2.68 (1.75%)

20:15
11/17/19
11/17
20:15
11/17/19
20:15
Earnings
Cabot Microelectronics sees Q1 total revenue approximately flat »

For Q1, the company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

CCMP

Cabot Microelectronics

$155.89

2.68 (1.75%)

20:14
11/17/19
11/17
20:14
11/17/19
20:14
Earnings
Cabot Microelectronics reports Q4 EPS $1.68, consensus $1.63 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

JEF

Jefferies Financial Group

$19.08

0.16 (0.85%)

20:13
11/17/19
11/17
20:13
11/17/19
20:13
Hot Stocks
Jefferies Financial Group to sell 31% interest in National Beef to Marfrig »

Jefferies Financial Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NIO

NIO Inc.

$1.82

0.07 (4.01%)

20:11
11/17/19
11/17
20:11
11/17/19
20:11
Hot Stocks
NIO Inc. appoints Wei Feng CFO »

NIO Inc. announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOLD

Barrick Gold

$16.57

-0.095 (-0.57%)

20:09
11/17/19
11/17
20:09
11/17/19
20:09
Hot Stocks
Barrick Gold to sell 50% stake in Australian mine for $750M in cash »

Barrick Gold Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOLD

Barrick Gold

$16.57

-0.095 (-0.57%)

15:40
11/17/19
11/17
15:40
11/17/19
15:40
Periodicals
Saracen close to buying Barrick Gold mine stake for $750M, Bloomberg says »

Saracen Mineral Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESPR

Esperion

$40.51

0.67 (1.68%)

15:11
11/17/19
11/17
15:11
11/17/19
15:11
Hot Stocks
Esperion presents pooled analyses from four Phase 3 bempedoic acid studies »

Esperion announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 26

    Feb

PCG

PG&E

$7.41

0.71 (10.60%)

15:06
11/17/19
11/17
15:06
11/17/19
15:06
Hot Stocks
PG&E monitoring potential weather event that could lead to power shutoffs »

Pacific Gas and Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

XRX

Xerox

$38.95

0.295 (0.76%)

, HPQ

HP Inc.

$20.17

0.05 (0.25%)

15:04
11/17/19
11/17
15:04
11/17/19
15:04
Hot Stocks
HP unanimously rejects unsolicited Xerox proposal »

HP Inc. (HPQ) announced…

XRX

Xerox

$38.95

0.295 (0.76%)

HPQ

HP Inc.

$20.17

0.05 (0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 09

    Dec

FOX

Fox Corp.

$33.60

0.14 (0.42%)

, FOXA

Fox Corp.

$34.26

0.04 (0.12%)

14:49
11/17/19
11/17
14:49
11/17/19
14:49
On The Fly
Box Office Battle: 'Ford v Ferrari' races to top, 'Charlie's Angels' disappoints »

"Box Office Battle" is…

FOX

Fox Corp.

$33.60

0.14 (0.42%)

FOXA

Fox Corp.

$34.26

0.04 (0.12%)

LGF.A

Lionsgate

$9.67

0.315 (3.37%)

LGF.B

Lionsgate

$9.07

0.345 (3.96%)

SNE

Sony

$62.03

0.23 (0.37%)

VIA

Viacom

$26.59

1.28 (5.06%)

VIAB

Viacom

$23.07

0.59 (2.62%)

T.CA

TELUS Corp. (Toronto)

$0.00

(0.00%)

CMCSA

Comcast

$44.54

-0.93 (-2.05%)

CMCSK

Comcast

$0.00

(0.00%)

DIS

Disney

$144.63

-2.56 (-1.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

JNJ

Johnson & Johnson

$134.97

3.99 (3.05%)

13:36
11/17/19
11/17
13:36
11/17/19
13:36
Periodicals
J&J rushed to test baby powder and got complicated results, WSJ says »

In October, Johnson &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

  • 07

    Dec

  • 21

    Jan

BA

Boeing

$371.55

4.25 (1.16%)

13:24
11/17/19
11/17
13:24
11/17/19
13:24
Periodicals
Boeing 737 makes emergency landing after engine malfunction, NY Post says »

A Canada-bound flight…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$47.46

0.09 (0.19%)

13:17
11/17/19
11/17
13:17
11/17/19
13:17
Hot Stocks
Data shows AstraZeneca's Brilinta reduces risks of clinically relevant bleeding »

New results from a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 07

    Dec

LLY

Eli Lilly

$113.18

1.8 (1.62%)

13:11
11/17/19
11/17
13:11
11/17/19
13:11
Hot Stocks
Analysis shows Jardiance decreased risk of hospitalization for heart failure »

A new interim analysis of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

AZN

AstraZeneca

$47.46

0.09 (0.19%)

13:09
11/17/19
11/17
13:09
11/17/19
13:09
Hot Stocks
AstraZeneca says data shows Farxiga reduces risks in heart failure patients »

AstraZeneca announced new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 07

    Dec

BA

Boeing

$371.55

4.25 (1.16%)

13:05
11/17/19
11/17
13:05
11/17/19
13:05
Hot Stocks
Boeing, Biman announce order for two 787-9 Dreamliner jets »

Boeing and Biman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBIO

BridgeBio

$28.26

0.55 (1.98%)

, EIDX

Eidos Therapeutics

$46.58

1.33 (2.94%)

13:03
11/17/19
11/17
13:03
11/17/19
13:03
Hot Stocks
BridgeBio, Eidos present 'positive' data from Phase 2 clinical trial of AG10 »

BridgeBio Pharma (BBIO)…

BBIO

BridgeBio

$28.26

0.55 (1.98%)

EIDX

Eidos Therapeutics

$46.58

1.33 (2.94%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 21

    Nov

CLBS

Caladrius

$2.64

-0.06 (-2.22%)

13:01
11/17/19
11/17
13:01
11/17/19
13:01
Hot Stocks
Caladrius reports 'positive' results for CLBS16 from ESCaPE-CMD trial »

Caladrius Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KNSA

Kiniksa

$6.52

0.1 (1.56%)

12:59
11/17/19
11/17
12:59
11/17/19
12:59
Hot Stocks
Kiniksa presents Rilonacept final Phase 2 clinical data »

Kiniksa Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 21

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.